Hemophagocytic Lymphohistiocytosis (HLH) is a rare life-threatening inflammatory response syndrome associated with immune deregulation, which is prone to misdiagnosis due to the lack of specificity of clinical symptoms, leading to poor prognosis. COVID-19 is an acute respiratory disease with high infectiousness caused by the novel coronavirus SARS-CoV-2. Currently, HLH induced by COVID-19 is rare, increasing the complexity of clinical diagnosis. In our hematology department, we encountered a case of HLH triggered by COVID-19 with severe condition. After the diagnosis was clarified, the patient received the HLH-2004 treatment programme immediately. The patient is currently in complete remission. Given the rarity of the reported cases, we would like to share this case to provide clinicians with insights for the diagnosis and treatment of the condition.
No takes yet. Share an insight, caveat, or question.
Yuexia Zhang (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: